HENDERSON, Nev., Nov. 6, 2024
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, has appointed
Timothy Still as Chairman of its
board of directors, effective November 06,
2024.
Mr. Still is currently Chairman and CEO of TSTILL Enterprises
LLC, and an Operating Partner with REVIVAL Healthcare. An
accomplished executive with a career spanning over 35 years in
medical diagnostics, devices and digital health, his background
includes extensive experience in designing and implementing highly
focused commercial and business development strategies within both
large and small companies. Tim has been directly responsible for
building the commercial viability at his previous companies, many
through to acquisition.
His most recent operating role was President and CEO of Sense
Biodetection. Early in 2023, Sense Bio merged with Sherlock
Biosciences to create a leading point of care diagnostics company
serving the consumer diagnostics market. Prior to Sense
Biodetection, Mr. Still has been a CEO and/or a board member at
numerous medical technology companies: Myoscience, MDx Health, Gold
Standard Diagnostics (Executive Chairman), Global Kinetics, Xagenic
and Accumetrics. Earlier in his career, Tim also held senior
leadership roles at HemoSense, Cholestech, and Boehringer
Mannheim/Roche.
Mr. Still has a master's degree in business administration
(Dean's Scholar) from the University of
Southern California, and a Bachelor of Science degree
(Highest Honors) from the University of
California at Davis.
Commenting on his appointment, Timothy
Still said:
"I am excited to join Volition at such a pivotal time in the
company's journey. With its groundbreaking epigenetic technology, I
believe Volition has the potential to significantly impact
global healthcare by detecting, guiding treatment, and monitoring
disease, to improve outcomes for people and animals worldwide. I
look forward to working alongside the board and leadership team
during this important next phase of growth at Volition."
Cameron Reynolds, President and
Group Chief Executive Officer, added:
"We are delighted to welcome Tim as Chairman of the Board of
Directors at Volition. He brings extensive experience in the
diagnostic sector and has a proven track record of successfully
guiding companies from the R&D phase to market readiness,
ultimately driving commercial success. We look forward to
benefiting from his strategic advice and leadership.
"I would like to thank Guy Innes,
who has acted as our Interim Non-Executive Chair since the summer
and continues to serve diligently on the Volition board."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases in both humans and animals. For more information about
Volition's technology go to: www.volition.com.
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is included
in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the potential uses, benefits and
effectiveness of Volition's Nu.Q® technology platform. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic, prognostic or disease monitoring
products, it may be unable to execute its plan of operations. Other
risks and uncertainties include Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; a failure by the marketplace to accept the
products in Volition's development pipeline or any other
diagnostic, prognostic or disease monitoring products Volition
might develop; Volition's failure to secure adequate intellectual
property protection; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring market
and its rapid technological change; downturns in domestic and
foreign economies; and other risks, including those identified in
Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. These statements
are based on current expectations, estimates and projections about
Volition's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this press release, and, except as required by law,
Volition does not undertake an obligation to update its
forward-looking statements to reflect future events or
circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Photo -
https://mma.prnewswire.com/media/2550489/Timothy_Still.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-appoints-timothy-i-still-as-chairman-302297781.html
SOURCE VolitionRx Limited